Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Analysis of Maternal Immune Profiles in Perinatal Depression with Selective Serotonin Reuptake Inhibitor (SSRI) Exposure
EF 2019-20
Résumé
"Approximately 15% of women are diagnosed with perinatal depression (PND), a subtype of major depressive disorder (MDD), that can occur during pregnancy or within the first year after birth. Mechanisms underlying perinatal susceptibility to depression are currently unknown, but recent research indicates inflammation may play an important role. In both pregnancy and depression, increases in immune inflammatory markers diminish with effective selective serotonin reuptake inhibitors (SSRIs) treatment of MDD. Ineffective SSRI treatment, where there are persistent depressive symptoms, coincides with elevated inflammation. However, no clinical studies examining depression or SSRI impacts on immune profiles have been completed in the perinatal period. To fill this gap, this study will use maternal blood samples obtained from a CIHR-funded longitudinal study examining prenatal maternal mood and SSRI exposure and infant development (Oberlander PI). Pregnancy blood samples were obtained from 3 groups of women: depressed with (1) and without (2) SSRI treatment, and healthy controls (3). Electrochemiluminescence will be used to measure blood immune markers. Both individual marker levels and immune marker networks will be assessed in relation to group. We hypothesize that the depressed without SSRIs group (2) will have higher levels of inflammatory cytokines, such as IL-6, TNF?, and IL-1?. Secondarily, the group with SSRI treatment (1) is expected to show attenuation of these pro-inflammatory cytokines in relation to positive maternal mood scores, as reported at various times in pregnancy and after birth. Exploring the relationships between maternal immune factors, PND and SSRI exposure may uncover the mechanisms that contribute to perinatal depression."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428732
Name
Clark Emily L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Analysis of Maternal Immune Profiles in Perinatal Depression with Selective Serotonin Reuptake Inhibitor (SSRI) Exposure
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antidepressants; Biomarkers; Cytokines; Depression; Inflammation; Interleukin-1beta; Interleukin-6; Maternal Health; Pregnancy; Serotonin Uptake Inhibitors
Abstract
"Approximately 15% of women are diagnosed with perinatal depression (PND), a subtype of major depressive disorder (MDD), that can occur during pregnancy or within the first year after birth. Mechanisms underlying perinatal susceptibility to depression are currently unknown, but recent research indicates inflammation may play an important role. In both pregnancy and depression, increases in immune inflammatory markers diminish with effective selective serotonin reuptake inhibitors (SSRIs) treatment of MDD. Ineffective SSRI treatment, where there are persistent depressive symptoms, coincides with elevated inflammation. However, no clinical studies examining depression or SSRI impacts on immune profiles have been completed in the perinatal period. To fill this gap, this study will use maternal blood samples obtained from a CIHR-funded longitudinal study examining prenatal maternal mood and SSRI exposure and infant development (Oberlander PI). Pregnancy blood samples were obtained from 3 groups of women: depressed with (1) and without (2) SSRI treatment, and healthy controls (3). Electrochemiluminescence will be used to measure blood immune markers. Both individual marker levels and immune marker networks will be assessed in relation to group. We hypothesize that the depressed without SSRIs group (2) will have higher levels of inflammatory cytokines, such as IL-6, TNF?, and IL-1?. Secondarily, the group with SSRI treatment (1) is expected to show attenuation of these pro-inflammatory cytokines in relation to positive maternal mood scores, as reported at various times in pregnancy and after birth. Exploring the relationships between maternal immune factors, PND and SSRI exposure may uncover the mechanisms that contribute to perinatal depression."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Clark, Emily L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~